

2016 PQRS

Recommended Measures for: Oncology & Hematology



Measures Groups

Reporting Requirements:

- Choose one (1) Measures Group
- Report on a minimum of 20 eligible patients (at least 11 must be Medicare Part B FFS patients)
- The numerator requirement must be met at least once for each reported measure

Oncology

- #71: Breast Cancer: Hormonal Therapy for Stage IC -IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
- #72: Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients
- #110: Preventive Care and Screening: Influenza Immunization
- #130: Documentation of Current Medications in the Medical Record
- #143: Oncology: Medical and Radiation – Pain Intensity Quantified
- #144: Oncology: Medical and Radiation – Plan of Care for Pain
- #226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

Individual Measures

Reporting Requirements:

- Report 9 measures across 3 National Quality Strategy (NQS) domains
- For each measure, report the quality action performed for at least 50% of the Medicare Part B FFS patients who are eligible for the measure.
- Include at least 1 cross-cutting measure **CC**
- The numerator requirement must be met at least once for each reported measure.

Measures by Quality Domain

Communication and Care Coordination

- #47: Care Plan **CC**
- #131: Pain Assessment and Follow-Up **CC**
- #265: Biopsy Follow-Up
- #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)
- #396: Lung Cancer Reporting (Resection Specimens)

Community/Population Health

- #134: Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan **CC**

Need more information? Connect with NJII PQRS Registry
973-642-4055 • pqrs@njii.com • www.njii.com/pqrs

2016 PQRS

Recommended Measures for: Oncology & Hematology



Effective Clinical Care

- #67: Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemia: Baseline Cytogenetic Testing Performed on Bone Marrow
- #68: Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
- #69: Hematology: Multiple Myeloma: Treatment with Bisphosphonates
- #70: Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry
- #71: Breast Cancer: Hormonal Therapy for Stage IC -IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
- #72: Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients
- #99: Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
- #100: Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
- #104: Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer
- #112: Breast Cancer Screening CC
- #113: Colorectal Cancer Screening

Efficiency and Cost Reduction

- #102: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients

Person and Caregiver-Centered Experience and Outcomes

- #143: Oncology: Medical and Radiation – Pain Intensity Quantified
- #144: Oncology: Medical and Radiation – Plan of Care for Pain
- #342: Pain Brought Under Control Within 48 Hours

Measures Applicability Validation (MAV) Clusters

View the [2016 PQRS MAV Process for Registry-Based Reporting of Individual Measures](#) for more details.

Cluster 5: Hematology Care

- #67: Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemia: Baseline Cytogenetic Testing Performed on Bone Marrow
- #68: Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
- #69: Hematology: Multiple Myeloma: Treatment with Bisphosphonates
- #70: Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry

Need more information? Connect with NJII PQRS Registry
973-642-4055 • pqrs@njii.com • www.njii.com/pqrs

2016 PQRS

Recommended Measures for: Oncology & Hematology



Cluster 7: Oncology Pain Care

- #131: Pain Assessment and Follow-Up **CC**
- #143: Oncology: Medical and Radiation – Pain Intensity Quantified
- #144: Oncology: Medical and Radiation – Plan of Care for Pain

Cluster 12: Pathology Breast Cancer

- #99: Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
- #251: Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients

Cluster 34: Pathology Lung Cancer

- #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)
- #396: Lung Cancer Reporting (Resection Specimens)

Cluster 40: Palliative Care

- #47: Care Plan **CC**
- #134: Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan **CC**
- #342: Pain Brought Under Control Within 48 Hours